{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T06:09:47Z","timestamp":1793340587451,"version":"4.5.0"},"reference-count":211,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["303095\/2021\\u20130"],"award-info":[{"award-number":["303095\/2021\\u20130"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["2016\/15603\\u20130"],"award-info":[{"award-number":["2016\/15603\\u20130"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["2021\/02401\\u20139"],"award-info":[{"award-number":["2021\/02401\\u20139"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["2019\/18431\\u20134"],"award-info":[{"award-number":["2019\/18431\\u20134"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["303095\/2021\\u20130"],"award-info":[{"award-number":["303095\/2021\\u20130"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Cancer Biology"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.semcancer.2025.07.001","type":"journal-article","created":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T11:02:54Z","timestamp":1751713374000},"page":"227-241","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Reopening Pandora\u2019s box: Is there a role for HDL in breast cancer?"],"prefix":"10.1016","volume":"114","author":[{"given":"Maria Isabela Bloise Alves Caldas","family":"Sawada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monique","family":"de Fatima de Mello Santana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milena Gomes","family":"Vancini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marisa","family":"Passarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semcancer.2025.07.001_bib1","series-title":"Breast Cancer [Internet]","first-page":"1","article-title":"The Epidemiology of Breast Cancer","author":"Arzanova","year":"2022"},{"key":"10.1016\/j.semcancer.2025.07.001_bib2","unstructured":"American Cancer Society. Cancer Facts and Figures 2024. Atlanta: American Cancer Society; 2024. \u3008https:\/\/www.cancer.org\/content\/dam\/cancer-org\/research\/cancer-facts-and-statistics\/annual-cancer-facts-and-figures\/2024\/2024-cancer-facts-and-figures-acs.pdf\u3009. Accessed on: August 11, 2024."},{"key":"10.1016\/j.semcancer.2025.07.001_bib3","unstructured":"Surveillance, Epidemiology, and End Results (SEER) Program. Breast cancer statistics. Dispon\u00edvel em: \u3008https:\/\/seer.cancer.gov\/statfacts\/html\/breast.html\u3009. Accessed on: August 11, 2024."},{"key":"10.1016\/j.semcancer.2025.07.001_bib4","series-title":"Breast cancer: facts & figures 2022 \u2013 2024","author":"American Cancer Society","year":"2022"},{"key":"10.1016\/j.semcancer.2025.07.001_bib5","first-page":"151","article-title":"Epidemiological characteristics of and risk factors for breast cancer in the world. Breast Cancer (Dove","volume":"11","author":"Momenimovahed","year":"2019","journal-title":"Med Press)"},{"issue":"12","key":"10.1016\/j.semcancer.2025.07.001_bib6","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1093\/aje\/kww145","article-title":"Population Attributable Risk of Modifiable and Nonmodifiable Breast Cancer Risk Factors in Postmenopausal Breast Cancer","volume":"184","author":"Tamimi","year":"2016","journal-title":"Am. J. Epidemiol."},{"issue":"11","key":"10.1016\/j.semcancer.2025.07.001_bib7","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S1470-2045(12)70425-4","article-title":"Menarche, menopause, and breast cancer risk: individual participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studies","volume":"13","author":"Collaborative Group on Hormonal Factors in Breast Cancer","year":"2012","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.semcancer.2025.07.001_bib8","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s12672-009-0003-0","article-title":"Circulating sex steroids and breast cancer risk in premenopausal women","volume":"1","author":"Hankinson","year":"2010","journal-title":"Horm Cancer. ("},{"issue":"2","key":"10.1016\/j.semcancer.2025.07.001_bib9","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S0002-9440(10)64879-1","article-title":"Breast cancer risk in usual ductal hyperplasia is defined by estrogen receptor-alpha and Ki-67 expression","volume":"160","author":"Shaaban","year":"2002","journal-title":"Am. J. Pathol."},{"issue":"2","key":"10.1016\/j.semcancer.2025.07.001_bib10","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1158\/1940-6207.CAPR-13-0222","article-title":"Understanding the premalignant potential of atypical hyperplasia through its natural history: a longitudinal cohort study","volume":"7","author":"Hartmann","year":"2014","journal-title":"Cancer Prev Res (Phila). ("},{"issue":"7","key":"10.1016\/j.semcancer.2025.07.001_bib11","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1038\/s41436-018-0361-5","article-title":"Clinical validity assessment of genes frequently tested on hereditary breast and ovarian cancer susceptibility sequencing panels","volume":"21","author":"Lee","year":"2019","journal-title":"Genet Med"},{"issue":"1","key":"10.1016\/j.semcancer.2025.07.001_bib12","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1001\/jamaoncol.2018.2956","article-title":"Association of Breast and Ovarian Cancers With Predisposition Genes Identified by Large-Scale Sequencing","volume":"5","author":"Lu","year":"2019","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.semcancer.2025.07.001_bib13","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d1016","article-title":"Association of active and passive smoking with risk of breast cancer among postmenopausal women: a prospective cohort study","volume":"342","author":"Luo","year":"2011","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.semcancer.2025.07.001_bib14","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1001\/archinternmed.2010.503","article-title":"Cigarette smoking and the incidence of breast cancer","volume":"171","author":"Xue","year":"2011","journal-title":"Arch. Intern Med"},{"issue":"7","key":"10.1016\/j.semcancer.2025.07.001_bib15","first-page":"667","article-title":"Breast cancer and exposure to tobacco smoke during potential windows of susceptibility","volume":"28","author":"White","year":"2017","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.semcancer.2025.07.001_bib16","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1146\/annurev.publhealth.19.1.101","article-title":"Environmental risk factors and female breast cancer","volume":"19","author":"Laden","year":"1998","journal-title":"Annu Rev. Public Health"},{"issue":"2","key":"10.1016\/j.semcancer.2025.07.001_bib17","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.ctrv.2014.12.002","article-title":"Diagnostic and therapeutic ionizing radiation and the risk of a first and second primary breast cancer, with special attention for BRCA1 and BRCA2 mutation carriers: a critical review of the literature","volume":"41","author":"Drooger","year":"2015","journal-title":"Cancer Treat. Rev."},{"issue":"1","key":"10.1016\/j.semcancer.2025.07.001_bib18","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1093\/aje\/kwaa163","article-title":"Evidence for Increased Susceptibility to Breast Cancer From Exposure to Ionizing Radiation Due to a Familial History of Breast Cancer: Results From the Swedish Hemangioma Cohort","volume":"190","author":"Eidem\u00fcller","year":"2021","journal-title":"Am. J. Epidemiol."},{"issue":"2","key":"10.1016\/j.semcancer.2025.07.001_bib19","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1016\/j.breast.2015.07.008","article-title":"Clinical implications of the intrinsic molecular subtypes of breast cancer","volume":"24","author":"Prat","year":"2015","journal-title":"Breast"},{"issue":"2","key":"10.1016\/j.semcancer.2025.07.001_bib20","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s12013-014-0459-6","article-title":"Breast Cancer: Epidemiology and Etiology","volume":"72","author":"Tao","year":"2015","journal-title":"Cell Biochem Biophys."},{"issue":"2","key":"10.1016\/j.semcancer.2025.07.001_bib21","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1053\/j.seminoncol.2019.03.002","article-title":"Invasive lobular breast cancer: A review of pathogenesis, diagnosis, management, and future directions of early stage disease","volume":"46","author":"Thomas","year":"2019","journal-title":"Semin Oncol."},{"issue":"8","key":"10.1016\/j.semcancer.2025.07.001_bib22","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1016\/j.cell.2023.01.040","article-title":"Deciphering breast cancer: from biology to the clinic","volume":"186","author":"Nolan","year":"2023","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.semcancer.2025.07.001_bib23","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1136\/jcp.55.2.88","article-title":"Long term prognostic value of Nottingham histological grade and its components in early (pT1N0M0) breast carcinoma","volume":"55","author":"Frkovic-Grazio","year":"2002","journal-title":"J. Clin. Pathol."},{"issue":"3","key":"10.1016\/j.semcancer.2025.07.001_bib24","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.7314\/APJCP.2014.15.3.1381","article-title":"Higher Ki67 expression is associates with unfavorable prognostic factors and shorter survival in breast cancer","volume":"15","author":"Kilickap","year":"2014","journal-title":"Asian Pac. J. Cancer Prev."},{"issue":"2","key":"10.1016\/j.semcancer.2025.07.001_bib25","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/S1470-2045(09)70262-1","article-title":"Ki67 in breast cancer: prognostic and predictive potential","volume":"11","author":"Yerushalmi","year":"2010","journal-title":"Lancet Oncol."},{"issue":"22","key":"10.1016\/j.semcancer.2025.07.001_bib26","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1093\/jnci\/djr393","article-title":"Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group","volume":"103","author":"Dowsett","year":"2011","journal-title":"J. Natl. Cancer Inst."},{"issue":"3","key":"10.1016\/j.semcancer.2025.07.001_bib27","doi-asserted-by":"crossref","first-page":"170","DOI":"10.4132\/jptm.2022.04.25","article-title":"What's new in breast pathology 2022: WHO 5th edition and biomarker updates","volume":"56","author":"Muller","year":"2022","journal-title":"J. Pathol. Transl. Med"},{"issue":"3","key":"10.1016\/j.semcancer.2025.07.001_bib28","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1053\/ctrv.2000.0207","article-title":"Prognostic and predictive factors in breast cancer","volume":"27","author":"Bundred","year":"2001","journal-title":"Cancer Treat. Rev."},{"issue":"6797","key":"10.1016\/j.semcancer.2025.07.001_bib29","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/35021093","article-title":"Molecular portraits of human breast tumours","volume":"406","author":"Perou","year":"2000","journal-title":"Nature"},{"issue":"7418","key":"10.1016\/j.semcancer.2025.07.001_bib30","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nature11412","article-title":"Comprehensive molecular portraits of human breast tumours","volume":"490","author":"Cancer Genome Atlas Network","year":"2012","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.semcancer.2025.07.001_bib31","doi-asserted-by":"crossref","first-page":"545","DOI":"10.5858\/arpa.2019-0904-SA","article-title":"Estrogen and Progesterone Receptor Testing in Breast Cancer: American Society of Clinical Oncology\/College of American Pathologists Guideline Update","volume":"144","author":"Allison","year":"2020","journal-title":"Arch. Pathol. Lab Med"},{"issue":"11","key":"10.1016\/j.semcancer.2025.07.001_bib32","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1111\/cas.12521","article-title":"Molecular mechanisms regulating the hormone sensitivity of breast cancer","volume":"105","author":"Tokunaga","year":"2014","journal-title":"Cancer Sci."},{"issue":"3","key":"10.1016\/j.semcancer.2025.07.001_bib33","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s10549-013-2699-3","article-title":"The molecular diversity of Luminal A breast tumors","volume":"141","author":"Ciriello","year":"2013","journal-title":"Breast Cancer Res Treat."},{"key":"10.1016\/j.semcancer.2025.07.001_bib34","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/3759179","article-title":"A Systematic Review of the Prevalence and Diagnostic Workup of PIK3CA Mutations in HR+\/HER2- Metastatic Breast Cancer","volume":"2020","author":"Anderson","year":"2020","journal-title":"Int J. Breast Cancer"},{"issue":"30","key":"10.1016\/j.semcancer.2025.07.001_bib35","doi-asserted-by":"crossref","first-page":"21444","DOI":"10.18632\/oncotarget.25118","article-title":"Functional significance of co-occurring mutations in PIK3CA and MAP3K1 in breast cancer","volume":"9","author":"Avivar-Valderas","year":"2018","journal-title":"Oncotarget"},{"issue":"22","key":"10.1016\/j.semcancer.2025.07.001_bib36","doi-asserted-by":"crossref","first-page":"3867","DOI":"10.1200\/JCO.22.02864","article-title":"Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: ASCO-College of American Pathologists Guideline Update","volume":"41","author":"Wolff","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2025.07.001_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2021.102286","article-title":"Targeting HER2 heterogeneity in breast cancer","volume":"100","author":"Hamilton","year":"2021","journal-title":"Cancer Treat. Rev."},{"issue":"5","key":"10.1016\/j.semcancer.2025.07.001_bib38","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1080\/02841860500543182","article-title":"TOP2A and HER2 gene amplification as predictors of response to anthracycline treatment in breast cancer","volume":"45","author":"Villman","year":"2006","journal-title":"Acta Oncol."},{"issue":"29","key":"10.1016\/j.semcancer.2025.07.001_bib39","doi-asserted-by":"crossref","first-page":"26560","DOI":"10.18632\/oncotarget.5306","article-title":"Triple negative breast cancer: looking for the missing link between biology and treatments","volume":"6","author":"Palma","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.semcancer.2025.07.001_bib40","unstructured":"Hortobagyi G.N. American Joint Comitee on Cancer (AJCC) Cancer Staging Mannual. The American College of Surgeons (ACS), Chapter 48, Eighth edition, Breast. Chicago, 2017."},{"issue":"2","key":"10.1016\/j.semcancer.2025.07.001_bib41","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1093\/annonc\/mdr129","article-title":"Breast cancer subtypes and outcome after local and regional relapse","volume":"23","author":"Montagna","year":"2012","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.semcancer.2025.07.001_bib42","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/cncr.28914","article-title":"Subtyping of triple-negative breast cancer: implications for therapy","volume":"121","author":"Abramson","year":"2015","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.semcancer.2025.07.001_bib43","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/j.drudis.2019.09.001","article-title":"PI3K\/AKT\/mTOR pathway inhibitors in triple-negative breast cancer: a review on drug discovery and future challenges","volume":"24","author":"Khan","year":"2019","journal-title":"Drug Discov. Today"},{"issue":"13","key":"10.1016\/j.semcancer.2025.07.001_bib44","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.3390\/cancers16132478","article-title":"Emerging Therapeutic Strategies to Overcome Drug Resistance in Cancer Cells","volume":"16","author":"Garg","year":"2024","journal-title":"Cancers (Basel). ("},{"issue":"1","key":"10.1016\/j.semcancer.2025.07.001_bib45","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1186\/s12885-019-5442-6","article-title":"Prognostic models for breast cancer: a systematic review","volume":"19","author":"Phung","year":"2019","journal-title":"BMC Cancer"},{"issue":"18","key":"10.1016\/j.semcancer.2025.07.001_bib46","doi-asserted-by":"crossref","first-page":"4976","DOI":"10.1158\/0008-5472.CAN-14-1756","article-title":"Obesity, cholesterol metabolism, and breast cancer pathogenesis","volume":"74","author":"McDonnell","year":"2014","journal-title":"Cancer Res"},{"key":"10.1016\/j.semcancer.2025.07.001_bib47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jsbmb.2018.05.001","article-title":"The contribution of cholesterol and epigenetic changes to the pathophysiology of breast cancer","volume":"183","author":"Munir","year":"2018","journal-title":"J. Steroid Biochem Mol. Biol."},{"key":"10.1016\/j.semcancer.2025.07.001_bib48","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41392-022-01125-5","article-title":"Regulation of cholesterol homeostasis in health and diseases: from mechanisms to targeted therapeutics","volume":"7","author":"Duan","year":"2022","journal-title":"Sig Transduct. Target Ther."},{"issue":"7","key":"10.1016\/j.semcancer.2025.07.001_bib49","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.tem.2017.03.002","article-title":"The Role of Oxysterols in Human Cancer","volume":"28","author":"Kloudova","year":"2017","journal-title":"Trends Endocrinol. Metab."},{"issue":"6","key":"10.1016\/j.semcancer.2025.07.001_bib50","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1172\/JCI0216388","article-title":"Do oxysterols control cholesterol homeostasis?","volume":"110","author":"Bj\u00f6rkhem","year":"2002","journal-title":"J. Clin. Invest"},{"issue":"2","key":"10.1016\/j.semcancer.2025.07.001_bib51","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.atherosclerosis.2010.10.042","article-title":"Plasma levels of 27-hydroxycholesterol in humans and mice with monogenic disturbances of high density lipoprotein metabolism","volume":"214","author":"Karuna","year":"2011","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.semcancer.2025.07.001_bib52","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.cofs.2021.08.001","article-title":"Oxysterols -how much do we know about food occurrence, dietary intake and absorption?","author":"Garcia-Llatas","year":"2021","journal-title":"Curr. Opin. Food Sci."},{"issue":"1","key":"10.1016\/j.semcancer.2025.07.001_bib53","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1210\/me.2007-0383","article-title":"27-hydroxycholesterol is an endogenous selective estrogen receptor modulator","volume":"22","author":"DuSell","year":"2008","journal-title":"Mol. Endocrinol."},{"issue":"3","key":"10.1016\/j.semcancer.2025.07.001_bib54","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.celrep.2013.10.006","article-title":"27-Hydroxycholesterol promotes cell-autonomous, ER-positive breast cancer growth","volume":"5","author":"Wu","year":"2013","journal-title":"Cell Rep."},{"issue":"6","key":"10.1016\/j.semcancer.2025.07.001_bib55","doi-asserted-by":"crossref","first-page":"617","DOI":"10.2217\/clp.14.53","article-title":"The interaction between metabolism, cancer and cardiovascular disease, connected by 27-hydroxycholesterol","volume":"9","author":"Lee","year":"2014","journal-title":"Clin. Lipido"},{"issue":"1","key":"10.1016\/j.semcancer.2025.07.001_bib56","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1038\/s41467-017-00910-z","article-title":"The cholesterol metabolite 27 hydroxycholesterol facilitates breast cancer metastasis through its actions on immune cells","volume":"8","author":"Baek","year":"2017","journal-title":"Nat. Commun."},{"issue":"20","key":"10.1016\/j.semcancer.2025.07.001_bib57","first-page":"4625","article-title":"Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma","volume":"56","author":"Leek","year":"1996","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.semcancer.2025.07.001_bib58","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1124\/mol.115.099598","article-title":"Marketed Drugs Can Inhibit Cytochrome P450 27A1, a Potential New Target for Breast Cancer Adjuvant Therapy","volume":"88","author":"Mast","year":"2015","journal-title":"Mol. Pharmacol."},{"issue":"6162","key":"10.1016\/j.semcancer.2025.07.001_bib59","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1126\/science.1241908","article-title":"27-Hydroxycholesterol links hypercholesterolemia and breast cancer pathophysiology","volume":"342","author":"Nelson","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.semcancer.2025.07.001_bib60","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.toxlet.2016.11.006","article-title":"The ROS-mediated activation of STAT-3\/VEGF signaling is involved in the 27-hydroxycholesterol-induced angiogenesis in human breast cancer cells","volume":"264","author":"Zhu","year":"2016","journal-title":"Toxicol. Lett."},{"key":"10.1016\/j.semcancer.2025.07.001_bib61","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.jsbmb.2016.06.010","article-title":"Circulating oxysterol metabolites as potential new surrogate markers in patients with hormone receptor-positive breast cancer: Results of the OXYTAM study","volume":"169","author":"Dalenc","year":"2017","journal-title":"J. Steroid Biochem Mol. Biol."},{"issue":"1","key":"10.1016\/j.semcancer.2025.07.001_bib62","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0016631","article-title":"The cholesterol metabolite 25-hydroxycholesterol activates estrogen receptor \u03b1-mediated signaling in cancer cells and in cardiomyocytes","volume":"6","author":"Lappano","year":"2011","journal-title":"PLoS One"},{"issue":"39","key":"10.1016\/j.semcancer.2025.07.001_bib63","doi-asserted-by":"crossref","first-page":"66033","DOI":"10.18632\/oncotarget.19789","article-title":"7-ketocholesterol and 27-hydroxycholesterol decreased doxorubicin sensitivity in breast cancer cells: estrogenic activity and mTOR pathway","volume":"8","author":"Wang","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.semcancer.2025.07.001_bib64","doi-asserted-by":"crossref","DOI":"10.1016\/j.biocel.2020.105876","article-title":"Cholesterol metabolism: At the cross road between cancer cells and immune environment","volume":"129","author":"Kopecka","year":"2020","journal-title":"Int J. Biochem Cell Biol."},{"issue":"7","key":"10.1016\/j.semcancer.2025.07.001_bib65","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1002\/eji.201344292","article-title":"Russo V. LXR-dependent and -independent effects of oxysterols on immunity and tumor growth","volume":"44","author":"Traversari","year":"2014","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.semcancer.2025.07.001_bib66","article-title":"Pleiotropic effects of statins: A focus on cancer","volume":"2020","author":"Ahmadi","year":"1866","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"10.1016\/j.semcancer.2025.07.001_bib67","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1186\/s13046-021-02041-2","article-title":"Statins: A repurposed drug to fight cancer","volume":"40","author":"Jiang","year":"2021","journal-title":"J. Exp. Clin. Cancer Res"},{"key":"10.1016\/j.semcancer.2025.07.001_bib68","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.trecan.2020.11.008","article-title":"Targeting the Mevalonate Pathway in Cancer","volume":"7","author":"Juarez","year":"2021","journal-title":"Trends Cancer"},{"key":"10.1016\/j.semcancer.2025.07.001_bib69","article-title":"New insights into the therapeutic potentials of statins in cancer","volume":"14","author":"Liu","year":"2023","journal-title":"Front. Pharm."},{"key":"10.1016\/j.semcancer.2025.07.001_bib70","article-title":"Regulation of PD-L1 through direct binding of cholesterol to CRAC motifs","volume":"8","author":"Wang","year":"2022","journal-title":"Sci. Adv."},{"issue":"1","key":"10.1016\/j.semcancer.2025.07.001_bib71","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12944-023-01807-1","article-title":"Lipid metabolism reprogramming in tumor-associated macrophages and implications for therapy","volume":"22","author":"Qiao","year":"2023","journal-title":"Lipids Health Dis."},{"key":"10.1016\/j.semcancer.2025.07.001_bib72","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1472-8206.2004.00299.x","article-title":"Chemical, pharmacokinetic and pharmacodynamic properties of statins: An update","volume":"19","author":"Schachter","year":"2005","journal-title":"Fundam. Clin. Pharm."},{"key":"10.1016\/j.semcancer.2025.07.001_bib73","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0197422","article-title":"Lipophilic statins limit cancer cell growth and survival, via involvement of Akt signaling","volume":"13","author":"Beckwitt","year":"2018","journal-title":"PLoS ONE"},{"key":"10.1016\/j.semcancer.2025.07.001_bib74","doi-asserted-by":"crossref","first-page":"3957","DOI":"10.1038\/s41467-018-06467-9","article-title":"A Mendelian randomization study of the effects of blood lipids on breast cancer risk","volume":"9","author":"Nowak","year":"2018","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.semcancer.2025.07.001_bib75","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s10549-022-06815-w","article-title":"Post-diagnostic statin use and breast cancer-specific mortality: a population-based cohort study","volume":"199","author":"Scott","year":"2023","journal-title":"Breast Cancer Res Treat."},{"issue":"5","key":"10.1016\/j.semcancer.2025.07.001_bib76","first-page":"532","article-title":"Role of Lipoproteins in the Pathophysiology of Breast Cancer","volume":"12","author":"Pandrangi","year":"2022","journal-title":"Membr. (Basel)"},{"issue":"1","key":"10.1016\/j.semcancer.2025.07.001_bib77","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13058-023-01636-1","article-title":"Modifiable risk factors in women at high risk of breast cancer: a systematic review","volume":"25","author":"Cohen","year":"2023","journal-title":"Breast Cancer Res"},{"issue":"1","key":"10.1016\/j.semcancer.2025.07.001_bib78","doi-asserted-by":"crossref","first-page":"8998","DOI":"10.1038\/s41598-023-35764-7","article-title":"Increased plasma lipids in triple-negative breast cancer and impairment in HDL functionality in advanced stages of tumors","volume":"13","author":"Sawada","year":"2023","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.semcancer.2025.07.001_bib79","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1186\/s12885-018-4568-2","article-title":"Impact of pre-diagnostic triglycerides and HDL-cholesterol on breast cancer recurrence and survival by breast cancer subtypes","volume":"18","author":"Lofter\u00f8d","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.semcancer.2025.07.001_bib80","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/1471-2407-14-132","article-title":"Plasma level of LDL-cholesterol at diagnosis is a predictor factor of breast tumor progression","volume":"14","author":"Rodrigues Dos Santos","year":"2014","journal-title":"BMC Cancer"},{"key":"10.1016\/j.semcancer.2025.07.001_bib81","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1017\/S000711451500183X","article-title":"Cholesterol and breast cancer risk: A systematic review and meta-analysis of prospective studies","volume":"114","author":"Touvier","year":"2015","journal-title":"Br. J. Nutr."},{"key":"10.1016\/j.semcancer.2025.07.001_bib82","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0142669","article-title":"Serum Lipids and Breast Cancer Risk: A Meta-Analysis of Prospective Cohort Studies","volume":"10","author":"Ni","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.semcancer.2025.07.001_bib83","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv032","article-title":"Serum Lipids, Lipoproteins, and Risk of Breast Cancer: A Nested Case-Control Study Using Multiple Time Points","volume":"107","author":"Martin","year":"2015","journal-title":"J. Natl. Cancer Inst."},{"issue":"6","key":"10.1016\/j.semcancer.2025.07.001_bib84","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.3945\/ajcn.115.124321","article-title":"Lipid biomarkers and long-term risk of cancer in the Women's Health Study","volume":"103","author":"Chandler","year":"2016","journal-title":"Am. J. Clin. Nutr."},{"key":"10.1016\/j.semcancer.2025.07.001_sbref82","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.tem.2023.02.009","article-title":"High-density lipoprotein cholesterol and carcinogenesis","volume":"34","author":"Tan","year":"2023","journal-title":"Trends Endocrinol. Metab."},{"issue":"4","key":"10.1016\/j.semcancer.2025.07.001_sbref83","doi-asserted-by":"crossref","first-page":"5756","DOI":"10.1002\/jcb.27862","article-title":"High-density lipoprotein functionality and breast cancer: A potential therapeutic target","volume":"120","author":"Samadi","year":"2019","journal-title":"J. Cell Biochem"},{"key":"10.1016\/j.semcancer.2025.07.001_bib86","doi-asserted-by":"crossref","first-page":"d1044","DOI":"10.2741\/1077","article-title":"High density lipoprotein structure","volume":"8","author":"Lund-Katz","year":"2003","journal-title":"Front Biosci."},{"issue":"6","key":"10.1016\/j.semcancer.2025.07.001_bib87","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1161\/CIRCRESAHA.116.309506","article-title":"HDL Particle Size and Functional Heterogeneity","volume":"119","author":"Fazio","year":"2016","journal-title":"Circ. Res"},{"issue":"3","key":"10.1016\/j.semcancer.2025.07.001_bib88","first-page":"281","article-title":"Cholesterol, lipoproteins, and breast cancer risk in African-American women","volume":"22","author":"Llanos","year":"2012","journal-title":"Ethn. Dis."},{"issue":"9","key":"10.1016\/j.semcancer.2025.07.001_bib89","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.annepidem.2008.06.006","article-title":"HDL-cholesterol and incidence of breast cancer in the ARIC cohort study","volume":"18","author":"Kucharska-Newton","year":"2008","journal-title":"Ann. Epidemiol."},{"issue":"2","key":"10.1016\/j.semcancer.2025.07.001_bib90","doi-asserted-by":"crossref","first-page":"e200","DOI":"10.5301\/jbm.5000143","article-title":"Decreased serum HDL at initial diagnosis correlates with worse outcomes for triple-negative breast cancer but not non-TNBCs","volume":"30","author":"Fan","year":"2015","journal-title":"Int J. Biol. Markers"},{"issue":"9","key":"10.1016\/j.semcancer.2025.07.001_bib91","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.3390\/jcm9092846","article-title":"Impact of Serum Lipid on Breast Cancer Recurrence","volume":"9","author":"Jung","year":"2020","journal-title":"J. Clin. Med"},{"key":"10.1016\/j.semcancer.2025.07.001_bib92","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.semcancer.2020.10.007","article-title":"HDL and cancer - causality still needs to be confirmed? Update 2020","volume":"73","author":"Ganjali","year":"2021","journal-title":"Semin Cancer Biol."},{"issue":"1","key":"10.1016\/j.semcancer.2025.07.001_bib93","first-page":"77","article-title":"Associations between serum lipids and breast cancer incidence and survival in the E3N prospective cohort study","volume":"28","author":"His","year":"2017","journal-title":"Cancer Causes Control"},{"issue":"6","key":"10.1016\/j.semcancer.2025.07.001_bib94","first-page":"483","article-title":"Association between high-density lipoprotein cholesterol and breast cancer varies by menopausal status","volume":"7","author":"Moorman","year":"1998","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"issue":"1","key":"10.1016\/j.semcancer.2025.07.001_bib95","doi-asserted-by":"crossref","first-page":"129","DOI":"10.4048\/jbc.2013.16.1.129","article-title":"Total cholesterol and triglyceride levels in patients with breast cancer","volume":"16","author":"Kapil","year":"2013","journal-title":"J. Breast Cancer"},{"issue":"15","key":"10.1016\/j.semcancer.2025.07.001_bib96","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1093\/jnci\/djh216","article-title":"Serum high-density lipoprotein cholesterol, metabolic profile, and breast cancer risk","volume":"96","author":"Furberg","year":"2004","journal-title":"J. Natl. Cancer Inst."},{"issue":"3","key":"10.1016\/j.semcancer.2025.07.001_bib97","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1097\/CEJ.0b013e3283240460","article-title":"Impact of metabolic factors on subsequent cancer risk: results from a large-scale population-based cohort study in Japan","volume":"18","author":"Inoue","year":"2009","journal-title":"Eur. J. Cancer Prev."},{"key":"10.1016\/j.semcancer.2025.07.001_bib98","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1158\/1055-9965.EPI-08-0133","article-title":"Serum high-density lipoprotein cholesterol and breast cancer risk by menopausal status, body mass index, and hormonal receptor in Korea","volume":"18","author":"Kim","year":"2009","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"issue":"2","key":"10.1016\/j.semcancer.2025.07.001_bib99","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s10654-014-9884-5","article-title":"Prospective associations between serum biomarkers of lipid metabolism and overall, breast and prostate cancer risk","volume":"29","author":"His","year":"2014","journal-title":"Eur. J. Epidemiol."},{"key":"10.1016\/j.semcancer.2025.07.001_bib100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.breast.2016.11.024","article-title":"The effect of preoperative serum triglycerides and high-density lipoprotein-cholesterol levels on the prognosis of breast cancer","volume":"32","author":"Li","year":"2017","journal-title":"Breast"},{"key":"10.1016\/j.semcancer.2025.07.001_bib101","doi-asserted-by":"crossref","first-page":"142","DOI":"10.4103\/ijpvm.IJPVM_285_20","article-title":"An Updated Systematic Review and Meta-Analysis on Association of Serum Lipid Profile With Risk of Breast Cancer Incidence","volume":"13","author":"Amerizadeh","year":"2022","journal-title":"Int J. Prev. Med"},{"key":"10.1016\/j.semcancer.2025.07.001_bib102","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s10549-023-06917-z","article-title":"Cholesterol and breast cancer risk: a cohort study using health insurance claims and health checkup databases","volume":"199","author":"Narii","year":"2023","journal-title":"Breast Cancer Res Treat."},{"issue":"4","key":"10.1016\/j.semcancer.2025.07.001_bib103","doi-asserted-by":"crossref","first-page":"5756","DOI":"10.1002\/jcb.27862","article-title":"High-density lipoprotein functionality and breast cancer: A potential therapeutic target","volume":"120","author":"Samadi","year":"2019","journal-title":"J. Cell Biochem"},{"issue":"12","key":"10.1016\/j.semcancer.2025.07.001_bib104","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1097\/GME.0b013e31828ce95d","article-title":"Metabolic syndrome and postmenopausal breast cancer: systematic review and meta-analysis","volume":"20","author":"Esposito","year":"2013","journal-title":"Menopause"},{"issue":"5","key":"10.1016\/j.semcancer.2025.07.001_bib105","first-page":"796","article-title":"Effect of preoperative total cholesterol and high-density lipoprotein-cholesterol levels on the prognosis of breast cancer[J]","volume":"20","author":"Cheng-wei","year":"2022","journal-title":"Chin. J. Gen. Pract."},{"issue":"3","key":"10.1016\/j.semcancer.2025.07.001_bib106","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s10549-016-3696-0","article-title":"High-density lipoprotein of patients with breast cancer complicated with type 2 diabetes mellitus promotes cancer cells adhesion to vascular endothelium via ICAM-1 and VCAM-1 upregulation","volume":"155","author":"Huang","year":"2016","journal-title":"Breast Cancer Res Treat."},{"issue":"1","key":"10.1016\/j.semcancer.2025.07.001_bib107","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/ijc.26341","article-title":"High-density lipoprotein of patients with type 2 diabetes mellitus elevates the capability of promoting migration and invasion of breast cancer cells","volume":"131","author":"Pan","year":"2012","journal-title":"Int J. Cancer"},{"issue":"16","key":"10.1016\/j.semcancer.2025.07.001_bib108","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1093\/eurheartj\/ehac605","article-title":"High-density lipoprotein revisited: biological functions and clinical relevance","volume":"44","author":"von Eckardstein","year":"2023","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.semcancer.2025.07.001_bib109","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.cca.2014.10.018","article-title":"Implications of reverse cholesterol transport: recent studies","volume":"439","author":"Levinson","year":"2015","journal-title":"Clin. Chim. Acta"},{"issue":"4","key":"10.1016\/j.semcancer.2025.07.001_bib110","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1128\/IAI.73.4.2321-2326.2005","article-title":"Lipopolysaccharide is transferred from high-density to low-density lipoproteins by lipopolysaccharide-binding protein and phospholipid transfer protein","volume":"73","author":"Levels","year":"2005","journal-title":"Infect. Immun."},{"issue":"1","key":"10.1016\/j.semcancer.2025.07.001_bib111","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1194\/jlr.E012138","article-title":"The role of HDL in innate immunity","volume":"52","author":"Feingold","year":"2011","journal-title":"J. Lipid Res"},{"issue":"12","key":"10.1016\/j.semcancer.2025.07.001_bib112","doi-asserted-by":"crossref","first-page":"549","DOI":"10.3390\/biomedicines8120549","article-title":"High-Density Lipoprotein Modifications: A Pathological Consequence or Cause of Disease Progression?","volume":"8","author":"M\u00e1rquez","year":"2020","journal-title":"Biomedicines"},{"key":"10.1016\/j.semcancer.2025.07.001_bib113","doi-asserted-by":"crossref","first-page":"222","DOI":"10.3389\/fphar.2015.00222","article-title":"Antioxidant properties of HDL","volume":"6","author":"Soran","year":"2015","journal-title":"Front Pharm."},{"key":"10.1016\/j.semcancer.2025.07.001_bib114","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.atherosclerosis.2016.11.015","article-title":"High density lipoproteins are modulators of protease activity: Implications in inflammation, complement activation, and atherothrombosis","volume":"259","author":"Gordon","year":"2017","journal-title":"Atherosclerosis"},{"issue":"6","key":"10.1016\/j.semcancer.2025.07.001_bib115","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S1050-1738(03)00098-7","article-title":"HDL stimulation of endothelial nitric oxide synthase: a novel mechanism of HDL action","volume":"13","author":"Mineo","year":"2003","journal-title":"Trends Cardiovasc Med"},{"issue":"4","key":"10.1016\/j.semcancer.2025.07.001_bib116","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nrendo.2011.235","article-title":"The emerging role of HDL in glucose metabolism","volume":"8","author":"Drew","year":"2012","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.semcancer.2025.07.001_bib117","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1007\/s00125-021-05509-0","article-title":"HDL and type 2 diabetes: the chicken or the egg?","volume":"64","author":"Xepapadaki","year":"2021","journal-title":"Diabetologia"},{"issue":"8","key":"10.1016\/j.semcancer.2025.07.001_bib118","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1161\/ATVBAHA.123.318267","article-title":"ApoA-I and Diabetes","volume":"43","author":"King","year":"2023","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.semcancer.2025.07.001_bib119","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2024.1377601","article-title":"Sphingosine-1-phosphate in the regulation of diabetes mellitus: a scientometric study to an in-depth review","volume":"15","author":"Li","year":"2024","journal-title":"Front Endocrinol. (Lausanne)"},{"issue":"7","key":"10.1016\/j.semcancer.2025.07.001_bib120","doi-asserted-by":"crossref","DOI":"10.1210\/endocr\/bqac072","article-title":"The Liver X Receptor Is Selectively Modulated to Differentially Alter Female Mammary Metastasis-associated Myeloid Cells","volume":"163","author":"Ma","year":"2022","journal-title":"Endocrinology"},{"issue":"9-10","key":"10.1016\/j.semcancer.2025.07.001_bib121","doi-asserted-by":"crossref","first-page":"309","DOI":"10.18632\/genesandcancer.122","article-title":"Identification of CETP as a molecular target for estrogen positive breast cancer cell death by cholesterol depleting agents","volume":"7","author":"Esau","year":"2016","journal-title":"Genes Cancer"},{"issue":"9","key":"10.1016\/j.semcancer.2025.07.001_bib122","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1002\/iub.2823","article-title":"Cholesteryl ester transfer protein knock-down in conjunction with a cholesterol-depleting agent decreases tamoxifen resistance in breast cancer cells","volume":"76","author":"Gu","year":"2024","journal-title":"IUBMB Life"},{"issue":"16","key":"10.1016\/j.semcancer.2025.07.001_bib123","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.3390\/cells13161327","article-title":"Proteomic Profiling of HDL in Newly Diagnosed Breast Cancer Based on Tumor Molecular Classification and Clinical Stage of Disease","volume":"13","author":"Santana","year":"2024","journal-title":"Cells"},{"key":"10.1016\/j.semcancer.2025.07.001_bib124","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12944-021-01562-1","article-title":"High density lipoproteins and oxidative stress in breast cancer","volume":"20","author":"Mazzuferi","year":"2021","journal-title":"Lipids Health Dis."},{"issue":"ement","key":"10.1016\/j.semcancer.2025.07.001_bib125","doi-asserted-by":"crossref","first-page":"S362","DOI":"10.4103\/0973-1482.235355","article-title":"Serum paraoxonase and arylesterase can be useful markers to predict neoadjuvant chemotherapy requirement in patients with breast cancer","volume":"14","author":"Okuturlar","year":"2018","journal-title":"J. Cancer Res Ther."},{"issue":"3","key":"10.1016\/j.semcancer.2025.07.001_bib126","doi-asserted-by":"crossref","first-page":"178","DOI":"10.4274\/ejbh.galenos.2024.2024-3-7","article-title":"Bioinformatic Investigation of Genetic Changes in Paraoxonase Genes in Breast Cancer and Breast Cancer Subtypes","volume":"20","author":"Ayan","year":"2024","journal-title":"Eur. J. Breast Health"},{"issue":"16-17","key":"10.1016\/j.semcancer.2025.07.001_bib127","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/j.clinbiochem.2012.05.021","article-title":"Paraoxonase 1 (PON1) as a marker of short term death in breast cancer recurrence","volume":"45","author":"Bobin-Dubigeon","year":"2012","journal-title":"Clin. Biochem"},{"issue":"6","key":"10.1016\/j.semcancer.2025.07.001_bib128","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.bbalip.2018.07.006","article-title":"Platelet-activating factor acetylhydrolases: An overview and update","volume":"1864","author":"Kono","year":"2019","journal-title":"Biochim Biophys. Acta Mol. Cell Biol. Lipids"},{"issue":"11","key":"10.1016\/j.semcancer.2025.07.001_bib129","doi-asserted-by":"crossref","first-page":"2950","DOI":"10.1194\/jlr.R036095","article-title":"Unraveling the complexities of the HDL lipidome","volume":"54","author":"Kontush","year":"2013","journal-title":"J. Lipid Res"},{"issue":"12","key":"10.1016\/j.semcancer.2025.07.001_bib130","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2024.100678","article-title":"Untargeted lipidomics reveals novel HDL metabotypes and lipid-clinical correlates","volume":"65","author":"Karmaus","year":"2024","journal-title":"J. Lipid Res"},{"issue":"2","key":"10.1016\/j.semcancer.2025.07.001_bib131","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.jss.2016.05.022","article-title":"High levels of sphingolipids in human breast cancer","volume":"204","author":"Nagahashi","year":"2016","journal-title":"J. Surg. Res"},{"issue":"1","key":"10.1016\/j.semcancer.2025.07.001_bib132","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s10549-018-4900-1","article-title":"Field template-based design and biological evaluation of new sphingosine kinase 1 inhibitors","volume":"172","author":"Alshaker","year":"2018","journal-title":"Breast Cancer Res Treat."},{"key":"10.1016\/j.semcancer.2025.07.001_bib133","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1111094","article-title":"The increased antioxidant action of HDL is independent of HDL cholesterol plasma levels in triple-negative breast cancer","volume":"13","author":"Campos","year":"2023","journal-title":"Front Oncol."},{"issue":"16","key":"10.1016\/j.semcancer.2025.07.001_bib134","doi-asserted-by":"crossref","first-page":"12762","DOI":"10.3390\/ijms241612762","article-title":"Increased Expression of miR-223-3p and miR-375-3p and Anti-Inflammatory Activity in HDL of Newly Diagnosed Women in Advanced Stages of Breast Cancer","volume":"24","author":"Santana","year":"2023","journal-title":"Int J. Mol. Sci."},{"issue":"67","key":"10.1016\/j.semcancer.2025.07.001_bib135","doi-asserted-by":"crossref","first-page":"7156","DOI":"10.18632\/oncotarget.27327","article-title":"Prognostic role of microRNAs in breast cancer: A systematic review","volume":"10","author":"Zografos","year":"2019","journal-title":"Oncotarget"},{"issue":"6","key":"10.1016\/j.semcancer.2025.07.001_bib136","doi-asserted-by":"crossref","first-page":"5008","DOI":"10.1002\/jcp.29396","article-title":"MicroRNAs in breast cancer: Roles, functions, and mechanism of actions","volume":"235","author":"Abolghasemi","year":"2020","journal-title":"J. Cell Physiol."},{"key":"10.1016\/j.semcancer.2025.07.001_bib137","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.atherosclerosis.2019.04.227","article-title":"High-density lipoproteins induce miR-223-3p biogenesis and export from myeloid cells: Role of scavenger receptor BI-mediated lipid transfer","volume":"286","author":"Cuesta Torres","year":"2019","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.semcancer.2025.07.001_bib138","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173359","article-title":"MiR-375 inhibits the stemness of breast cancer cells by blocking the JAK2\/STAT3 signaling","volume":"884","author":"Zhao","year":"2020","journal-title":"Eur. J. Pharm."},{"issue":"10","key":"10.1016\/j.semcancer.2025.07.001_bib139","first-page":"1494","article-title":"The Role of miR-375-3p, miR-210-3p and Let-7e-5p in the Pathological Response of Breast Cancer Patients to Neoadjuvant Therapy","volume":"58","author":"Lisencu","year":"2022","journal-title":"Med. (Kaunas. ). ("},{"issue":"1","key":"10.1016\/j.semcancer.2025.07.001_bib140","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexcr.2021.112507","article-title":"MiR-375 silencing attenuates pro-inflammatory macrophage response and foam cell formation by targeting KLF4","volume":"400","author":"Qiu","year":"2021","journal-title":"Exp. Cell Res"},{"issue":"3","key":"10.1016\/j.semcancer.2025.07.001_bib141","doi-asserted-by":"crossref","first-page":"574","DOI":"10.3390\/cells10030574","article-title":"High Density Lipoprotein Cholesterol Efflux Capacity and Atherosclerosis in Cardiovascular Disease: Pathophysiological Aspects and Pharmacological Perspectives","volume":"10","author":"Adorni","year":"2021","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.semcancer.2025.07.001_bib142","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1194\/jlr.M019976","article-title":"ATP hydrolysis-dependent conformational changes in the extracellular domain of ABCA1 are associated with apoA-I binding","volume":"53","author":"Nagao","year":"2012","journal-title":"J. Lipid Res"},{"issue":"1","key":"10.1016\/j.semcancer.2025.07.001_bib143","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/00041433-200502000-00005","article-title":"ATP-binding cassette transporter AI and its role in HDL formation","volume":"16","author":"Lee","year":"2005","journal-title":"Curr. Opin. Lipido"},{"issue":"10","key":"10.1016\/j.semcancer.2025.07.001_bib144","doi-asserted-by":"crossref","first-page":"8815","DOI":"10.1074\/jbc.M206885200","article-title":"Effects of mutations of ABCA1 in the first extracellular domain on subcellular trafficking and ATP binding\/hydrolysis","volume":"278","author":"Tanaka","year":"2003","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.semcancer.2025.07.001_bib145","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.3390\/ijms24021290","article-title":"Identification of Side Chain Oxidized Sterols as Novel Liver X Receptor Agonists with Therapeutic Potential in the Treatment of Cardiovascular and Neurodegenerative Diseases","volume":"24","author":"Zhan","year":"2023","journal-title":"Int J. Mol. Sci."},{"issue":"38","key":"10.1016\/j.semcancer.2025.07.001_bib146","doi-asserted-by":"crossref","first-page":"27816","DOI":"10.1074\/jbc.M603781200","article-title":"Sterol intermediates from cholesterol biosynthetic pathway as liver X receptor ligands","volume":"281","author":"Yang","year":"2006","journal-title":"J. Biol. Chem."},{"issue":"10","key":"10.1016\/j.semcancer.2025.07.001_bib147","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0046456","article-title":"The lipid phenotype of breast cancer cells characterized by Raman microspectroscopy: towards a stratification of malignancy","volume":"7","author":"Nieva","year":"2012","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.semcancer.2025.07.001_bib148","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1055\/s-0029-1241859","article-title":"Expression of the lipid transporters ABCA3 and ABCA1 is diminished in human breast cancer tissue","volume":"42","author":"Schimanski","year":"2010","journal-title":"Horm. Metab. Res"},{"issue":"3","key":"10.1016\/j.semcancer.2025.07.001_bib149","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.celrep.2012.08.011","article-title":"Anticancer activity of the cholesterol exporter ABCA1 gene","volume":"2","author":"Smith","year":"2012","journal-title":"Cell Rep."},{"issue":"2","key":"10.1016\/j.semcancer.2025.07.001_bib150","first-page":"485","article-title":"ABCA1 is associated with the development of acquired chemotherapy resistance and predicts poor ovarian cancer outcome","volume":"4","author":"Wang","year":"2021","journal-title":"Cancer Drug Resist"},{"issue":"5","key":"10.1016\/j.semcancer.2025.07.001_bib151","first-page":"1869","article-title":"Expression of LXR \u03b2, ABCA1 and ABCG1 in human triple negative breast cancer tissues","volume":"42","author":"Pan","year":"2019","journal-title":"Oncol. Rep."},{"issue":"9","key":"10.1016\/j.semcancer.2025.07.001_bib152","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.biopha.2015.08.032","article-title":"Reversal of chemoresistance with small interference RNA (siRNA) in etoposide resistant acute myeloid leukemia cells (HL-60)","volume":"75","author":"Kachalaki","year":"2015","journal-title":"Biomed. Pharm."},{"issue":"3","key":"10.1016\/j.semcancer.2025.07.001_bib153","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.cell.2018.11.011","article-title":"p53 Represses the Mevalonate Pathway to Mediate Tumor Suppression","volume":"176","author":"Moon","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.semcancer.2025.07.001_bib154","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/1476-4598-8-129","article-title":"Overexpression of the ATP binding cassette gene ABCA1 determines resistance to Curcumin in M14 melanoma cells","volume":"8","author":"Bachmeier","year":"2009","journal-title":"Mol. Cancer"},{"issue":"5","key":"10.1016\/j.semcancer.2025.07.001_bib155","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.3892\/or.2016.4631","article-title":"MiR-183 functions as an oncogene by targeting ABCA1 in colon cancer","volume":"35","author":"Bi","year":"2016","journal-title":"Oncol. Rep."},{"issue":"7","key":"10.1016\/j.semcancer.2025.07.001_bib156","first-page":"3007","article-title":"LXR Agonists and ABCG1-Dependent Cholesterol Efflux in MCF-7 Breast Cancer Cells: Relation to Proliferation and Apoptosis","volume":"32","author":"El Roz","year":"2012","journal-title":"Anticancer Res"},{"issue":"18","key":"10.1016\/j.semcancer.2025.07.001_bib157","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1038\/onc.2010.30","article-title":"Liver X Receptor activation downregulates AKT survival signaling in lipid rafts and induces apoptosis of prostate cancer cells","volume":"29","author":"Pommier","year":"2010","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.semcancer.2025.07.001_bib158","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1080\/19336950.2021.1909301","article-title":"Diagnostic and prognostic value of ABC transporter family member ABCG1 gene in clear cell renal cell carcinoma","volume":"15","author":"Meng","year":"2021","journal-title":"Channels (Austin). ("},{"issue":"5986","key":"10.1016\/j.semcancer.2025.07.001_bib159","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1126\/science.1189731","article-title":"ATP-binding cassette transporters and HDL suppress hematopoietic stem cell proliferation","volume":"328","author":"Yvan-Charvet","year":"2010","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.semcancer.2025.07.001_bib160","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2133\/dmpk.DMPK-11-RV-098","article-title":"Functional significance of genetic polymorphisms in P-glycoprotein (MDR1, ABCB1) and breast cancer resistance protein (BCRP, ABCG2","volume":"27","author":"Ieiri","year":"2012","journal-title":"Drug Metab. Pharm."},{"issue":"1","key":"10.1016\/j.semcancer.2025.07.001_bib161","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.canlet.2005.04.024","article-title":"Localization of the ABCG2 mitoxantrone resistance-associated protein in normal tissues","volume":"235","author":"Fetsch","year":"2006","journal-title":"Cancer Lett."},{"issue":"2","key":"10.1016\/j.semcancer.2025.07.001_bib162","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/path.1203","article-title":"Frequent expression of the multi-drug resistance-associated protein BCRP\/MXR\/ABCP\/ABCG2 in human tumours detected by the BXP-21 monoclonal antibody in paraffin-embedded material","volume":"198","author":"Diestra","year":"2002","journal-title":"J. Pathol."},{"issue":"3","key":"10.1016\/j.semcancer.2025.07.001_bib163","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1159\/000520871","article-title":"Expression of BCRP\/ABCG2 Protein in Invasive Breast Cancer and Response to Neoadjuvant Chemotherapy","volume":"45","author":"Zhang","year":"2022","journal-title":"Oncol. Res Treat."},{"issue":"11","key":"10.1016\/j.semcancer.2025.07.001_bib164","doi-asserted-by":"crossref","first-page":"3891","DOI":"10.31557\/APJCP.2023.24.11.3891","article-title":"Association of ABCG2 Polymorphisms on Triple Negative Breast Cancer (TNBC) Susceptibility Risk","volume":"24","author":"Hao Ing","year":"2023","journal-title":"Asian Pac. J. Cancer Prev."},{"issue":"3","key":"10.1016\/j.semcancer.2025.07.001_bib165","doi-asserted-by":"crossref","first-page":"393","DOI":"10.2174\/1574892816666210218220531","article-title":"A Combined Bioinformatic and Nanoparticle-Based Study Reveal the Role of ABCG2 in the Drug Resistant Breast Cancer","volume":"16","author":"Huo","year":"2021","journal-title":"Recent Pat. Anticancer Drug Discov."},{"issue":"3","key":"10.1016\/j.semcancer.2025.07.001_bib166","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s12282-020-01210-z","article-title":"Friend or foe: ABCG2, ABCC1 and ABCB1 expression in triple-negative breast cancer","volume":"28","author":"Nedeljkovi\u0107","year":"2021","journal-title":"Breast Cancer"},{"issue":"1","key":"10.1016\/j.semcancer.2025.07.001_bib167","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1161\/ATVBAHA.117.305140","article-title":"Rosuvastatin Reduces Aortic Sinus and Coronary Artery Atherosclerosis in SR-B1 (Scavenger Receptor Class B Type 1)\/ApoE (Apolipoprotein E) Double Knockout Mice Independently of Plasma Cholesterol Lowering","volume":"38","author":"Yu","year":"2018","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"7757","key":"10.1016\/j.semcancer.2025.07.001_bib168","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/s41586-019-1140-4","article-title":"SR-B1 drives endothelial cell LDL transcytosis via DOCK4 to promote atherosclerosis","volume":"569","author":"Huang","year":"2019","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.semcancer.2025.07.001_bib169","doi-asserted-by":"crossref","DOI":"10.1172\/JCI94229","article-title":"Macrophage SR-BI modulates autophagy via VPS34 complex and PPAR\u03b1 transcription of Tfeb in atherosclerosis","volume":"131","author":"Tao","year":"2021","journal-title":"J. Clin. Invest"},{"issue":"7","key":"10.1016\/j.semcancer.2025.07.001_bib170","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1194\/jlr.R083121","article-title":"Scavenger receptor B type 1: expression, molecular regulation, and cholesterol transport function","volume":"59","author":"Shen","year":"2018","journal-title":"J. Lipid Res"},{"key":"10.1016\/j.semcancer.2025.07.001_bib171","doi-asserted-by":"crossref","first-page":"466","DOI":"10.3389\/fphar.2016.00466","article-title":"Targeting the SR-B1 Receptor as a Gateway for Cancer Therapy and Imaging","volume":"7","author":"Mooberry","year":"2016","journal-title":"Front. Pharm."},{"issue":"6","key":"10.1016\/j.semcancer.2025.07.001_bib172","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.tem.2017.02.001","article-title":"SR-BI: A Multifunctional Receptor in Cholesterol Homeostasis and Atherosclerosis","volume":"28","author":"Linton","year":"2017","journal-title":"Trends Endocrinol. Metab."},{"issue":"6","key":"10.1016\/j.semcancer.2025.07.001_bib173","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1161\/ATVBAHA.109.184663","article-title":"Role of 3beta-hydroxysteroid-delta 24 reductase in mediating antiinflammatory effects of high-density lipoproteins in endothelial cells","volume":"29","author":"McGrath","year":"2009","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"6","key":"10.1016\/j.semcancer.2025.07.001_bib174","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.coph.2012.07.009","article-title":"Cholesterol and breast cancer development","volume":"12","author":"Danilo","year":"2012","journal-title":"Curr. Opin. Pharm."},{"issue":"3","key":"10.1016\/j.semcancer.2025.07.001_bib175","doi-asserted-by":"crossref","first-page":"3581","DOI":"10.1007\/s13277-015-4141-4","article-title":"High scavenger receptor class B type I expression is related to tumor aggressiveness and poor prognosis in breast cancer","volume":"37","author":"Yuan","year":"2016","journal-title":"Tumour Biol."},{"issue":"5","key":"10.1016\/j.semcancer.2025.07.001_bib176","doi-asserted-by":"crossref","first-page":"R87","DOI":"10.1186\/bcr3483","article-title":"Scavenger receptor class B type I regulates cellular cholesterol metabolism and cell signaling associated with breast cancer development","volume":"15","author":"Danilo","year":"2013","journal-title":"Breast Cancer Res"},{"issue":"1","key":"10.1016\/j.semcancer.2025.07.001_bib177","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.ajpath.2010.11.005","article-title":"Role of cholesterol in the development and progression of breast cancer","volume":"178","author":"Llaverias","year":"2011","journal-title":"Am. J. Pathol."},{"issue":"4","key":"10.1016\/j.semcancer.2025.07.001_bib178","article-title":"Prognostic and clinicopathological significance of SR-B1 in solid tumors: A meta-analysis","volume":"216","author":"Wang","year":"2020","journal-title":"Pathol. Res Pr."},{"issue":"4","key":"10.1016\/j.semcancer.2025.07.001_bib179","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1158\/0008-5472.CAN-03-0675","article-title":"A mutant high-density lipoprotein receptor inhibits proliferation of human breast cancer cells","volume":"64","author":"Cao","year":"2004","journal-title":"Cancer Res"},{"issue":"8","key":"10.1016\/j.semcancer.2025.07.001_bib180","first-page":"1069","article-title":"Expression of SR-B1 receptor in breast cancer cell lines, MDAMB-468 and MCF-7: Effect on cell proliferation and apoptosis","volume":"24","author":"Karimi","year":"2021","journal-title":"Iran. J. Basic Med Sci."},{"issue":"1","key":"10.1016\/j.semcancer.2025.07.001_bib181","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/jcb.10724","article-title":"Cholesterol and prostate cancer","volume":"91","author":"Freeman","year":"2004","journal-title":"J. Cell Biochem"},{"issue":"1","key":"10.1016\/j.semcancer.2025.07.001_bib182","first-page":"1","volume":"396","author":"De Gonzalo-Calvo","year":"2015","journal-title":"Biol. Chem."},{"issue":"16","key":"10.1016\/j.semcancer.2025.07.001_bib183","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1007\/s00018-012-1194-z","article-title":"LOX-1 in atherosclerosis: biological functions and pharmacological modifiers","volume":"70","author":"Xu","year":"2013","journal-title":"Cell Mol. Life Sci."},{"key":"10.1016\/j.semcancer.2025.07.001_bib184","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.ccr.2010.01.022","article-title":"A transcriptional signature and common gene networks link cancer with lipid metabolism and diverse human diseases","volume":"17","author":"Hirsch","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.semcancer.2025.07.001_bib185","doi-asserted-by":"crossref","first-page":"44","DOI":"10.20892\/j.issn.2095-3941.2019.0210","article-title":"Metabolic reprogramming in triple-negative breast cancer","volume":"17","author":"Wang","year":"2020","journal-title":"Cancer Biol. Med"},{"key":"10.1016\/j.semcancer.2025.07.001_bib186","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41419-018-1279-1","article-title":"Pro-oncogenic action of LOX-1 and its splice variant LOX-1\u03944 in breast cancer phenotypes","volume":"10","author":"Pucci","year":"2019","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.semcancer.2025.07.001_bib187","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.canlet.2007.08.003","article-title":"Up-regulation of LOX-1 expression by TNF-\u03b1 promotes trans-endothelial migration of MDA-MB-231 breast cancer cells","volume":"258","author":"Liang","year":"2007","journal-title":"Cancer Lett."},{"key":"10.1016\/j.semcancer.2025.07.001_bib188","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.3892\/or.2015.3880","article-title":"Adipocyte hypoxia promotes epithelial-mesenchymal transition-related gene expression and estrogen receptor-negative phenotype in breast cancer cells","volume":"33","author":"Yao-Borengasser","year":"2015","journal-title":"Oncol. Rep."},{"issue":"10-11","key":"10.1016\/j.semcancer.2025.07.001_bib189","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1038\/s41417-020-00279-0","article-title":"LOX-1 and cancer: an indissoluble liaison","volume":"28","author":"Murdocca","year":"2021","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.semcancer.2025.07.001_bib190","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s11010-017-3055-4","article-title":"SCARA5 plays a critical role in the progression and metastasis of breast cancer by inactivating the ERK1\/2, STAT3, and AKT signaling pathways","volume":"435","author":"You","year":"2017","journal-title":"Mol. Cell Biochem"},{"issue":"3","key":"10.1016\/j.semcancer.2025.07.001_bib191","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s10549-018-4992-7","article-title":"Advanced glycation end products are elevated in estrogen receptor-positive breast cancer patients, alter response to therapy, and can be targeted by lifestyle intervention","volume":"173","author":"Walter","year":"2019","journal-title":"Breast Cancer Res Treat."},{"issue":"3","key":"10.1016\/j.semcancer.2025.07.001_bib192","first-page":"219","article-title":"Carbonyl and oxidative stress in patients with breast cancer--is there a relation to the stage of the disease?","volume":"54","author":"Tesarov\u00e1","year":"2007","journal-title":"Neoplasma"},{"issue":"5","key":"10.1016\/j.semcancer.2025.07.001_bib193","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s00418-016-1534-4","article-title":"Accumulation of the advanced glycation end product carboxymethyl lysine in breast cancer is positively associated with estrogen receptor expression and unfavorable prognosis in estrogen receptor-negative cases","volume":"147","author":"Nass","year":"2017","journal-title":"Histochem Cell Biol."},{"issue":"2","key":"10.1016\/j.semcancer.2025.07.001_bib194","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2021-002697","article-title":"Advanced glycation end products correlate with breast cancer metastasis by activating RAGE\/TLR4 signaling","volume":"10","author":"Pan","year":"2022","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"10","key":"10.1016\/j.semcancer.2025.07.001_bib195","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1159\/000449326","article-title":"Increased Expression of the Receptor for Advanced Glycation End-Products (RAGE) Is Associated with Advanced Breast Cancer Stage","volume":"39","author":"Nankali","year":"2016","journal-title":"Oncol. Res Treat."},{"issue":"6","key":"10.1016\/j.semcancer.2025.07.001_bib196","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1158\/0008-5472.CAN-14-2161","article-title":"RAGE mediates S100A7-induced breast cancer growth and metastasis by modulating the tumor microenvironment","volume":"75","author":"Nasser","year":"2015","journal-title":"Cancer Res"},{"issue":"11","key":"10.1016\/j.semcancer.2025.07.001_bib197","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1038\/onc.2016.324","article-title":"Targeting Of Rage-Ligand Signaling Impairs Breast Cancer Cell Invasion And Metastasis","volume":"36","author":"Kwak","year":"2017","journal-title":"Oncogene"},{"issue":"7","key":"10.1016\/j.semcancer.2025.07.001_bib198","doi-asserted-by":"crossref","DOI":"10.1177\/1010428317702902","article-title":"Kubena Aa, Kalousova M. Polymorphisms Of The Receptor For Advanced Glycation End Products And Glyoxalase I And Long-Term Outcome In Patients With Breast Cancer","volume":"39","author":"Tesarov\u00e1","year":"2017","journal-title":"Tumour Biol."},{"issue":"1","key":"10.1016\/j.semcancer.2025.07.001_bib199","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s13058-023-01689-2","article-title":"Publisher Correction: RAGE inhibition blunts insulin-induced oncogenic signals in breast cancer","volume":"25","author":"Muoio","year":"2023","journal-title":"Breast Cancer Res"},{"issue":"8","key":"10.1016\/j.semcancer.2025.07.001_bib200","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1080\/07357900701560521","article-title":"Receptor for advanced glycation end products (RAGE)--soluble form (sRAGE) and gene polymorphisms in patients with breast cancer","volume":"25","author":"Tesarov\u00e1","year":"2007","journal-title":"Cancer Invest"},{"issue":"24","key":"10.1016\/j.semcancer.2025.07.001_bib201","doi-asserted-by":"crossref","first-page":"6124","DOI":"10.3390\/cancers14246124","article-title":"Genetically Modified Circulating Levels of Advanced Glycation End-Products and Their Soluble Receptor (AGEs-RAGE Axis) with Risk and Mortality of Breast Cancer","volume":"14","author":"Peng","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.semcancer.2025.07.001_bib202","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s12282-018-00935-2","article-title":"Toll-like receptor 4 and breast cancer: an updated systematic review","volume":"26","author":"Khademalhosseini","year":"2019","journal-title":"Breast Cancer"},{"issue":"25","key":"10.1016\/j.semcancer.2025.07.001_bib203","doi-asserted-by":"crossref","first-page":"E3216","DOI":"10.1073\/pnas.1420811112","article-title":"TLR4 has a TP53-dependent dual role in regulating breast cancer cell growth","volume":"112","author":"Haricharan","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"3","key":"10.1016\/j.semcancer.2025.07.001_bib204","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1007\/s10549-011-1844-0","article-title":"Triggering of Toll-like receptor 4 on metastatic breast cancer cells promotes \u03b1v\u03b23-mediated adhesion and invasive migration","volume":"133","author":"Liao","year":"2012","journal-title":"Breast Cancer Res Treat."},{"issue":"2","key":"10.1016\/j.semcancer.2025.07.001_bib205","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1177\/0885328219850759","article-title":"High density lipoprotein coated calcium carbonate nanoparticle for chemotherapy of breast cancer","volume":"34","author":"Wei","year":"2019","journal-title":"J. Biomater. Appl."},{"issue":"1","key":"10.1016\/j.semcancer.2025.07.001_bib206","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1080\/10717544.2019.1618420","article-title":"Development of synthetic high-density lipoprotein-based ApoA-I mimetic peptide-loaded docetaxel as a drug delivery nanocarrier for breast cancer chemotherapy","volume":"26","author":"Gong","year":"2019","journal-title":"Drug Deliv."},{"key":"10.1016\/j.semcancer.2025.07.001_bib207","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.jconrel.2024.01.064","article-title":"Adenosine-modulating synthetic high-density lipoprotein for chemoimmunotherapy of triple-negative breast cancer","volume":"367","author":"Gong","year":"2024","journal-title":"J. Control Release"},{"issue":"9","key":"10.1016\/j.semcancer.2025.07.001_bib208","doi-asserted-by":"crossref","first-page":"3726","DOI":"10.1016\/j.apsb.2022.02.021","article-title":"Lenvatinib- and vadimezan-loaded synthetic high-density lipoprotein for combinational immunochemotherapy of metastatic triple-negative breast cancer","volume":"12","author":"Zheng","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"issue":"30","key":"10.1016\/j.semcancer.2025.07.001_bib209","doi-asserted-by":"crossref","first-page":"35248","DOI":"10.1021\/acsami.1c02074","article-title":"Peptide-Targeted High-Density Lipoprotein Nanoparticles for Combinatorial Treatment against Metastatic Breast Cancer","volume":"13","author":"Jiang","year":"2021","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.semcancer.2025.07.001_bib210","doi-asserted-by":"crossref","DOI":"10.1038\/srep36387","article-title":"ApoA-I mimetic administration, but not increased apoA-I-containing HDL, inhibits tumour growth in a mouse model of inherited breast cancer","volume":"6","author":"Ced\u00f3","year":"2016","journal-title":"Sci. Rep."}],"container-title":["Seminars in Cancer Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044579X2500094X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044579X2500094X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T10:43:30Z","timestamp":1778582610000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1044579X2500094X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":211,"alternative-id":["S1044579X2500094X"],"URL":"https:\/\/doi.org\/10.1016\/j.semcancer.2025.07.001","relation":{},"ISSN":["1044-579X"],"issn-type":[{"value":"1044-579X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reopening Pandora\u2019s box: Is there a role for HDL in breast cancer?","name":"articletitle","label":"Article Title"},{"value":"Seminars in Cancer Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semcancer.2025.07.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}